-
CORXEL Gets CDE Approval for Phase III Presbyopia Trials of LNZ100 and LNZ101
•
Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has announced that it has received approval from the Center for Drug Evaluation (CDE) to conduct Phase III clinical trials for its LNZ100 (aceclidine) and LNZ101 (aceclidine/brimonidine) in presbyopia. Exclusive Rights and Licensing Deal with LENZ TherapeuticsJi Xing…
-
Lee’s Pharmaceutical Subsidiary Zhaoke Ophthalmology Partners with Eyebright Medical Technology
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has entered into a partnership with Beijing-headquartered ophthalmic device manufacturer, Eyebright Medical Technology Co., Ltd (SHA: 688050). The collaboration aims to enhance the development and commercialization of ophthalmic drugs and medical devices. Comprehensive Collaboration in OphthalmologyUnder the…
-
BeiGene and Bristol-Myers Squibb/Celgene Settle Partnership, Termination Set for 2023
•
BeiGene (NASDAQ: BGNE) has announced a settlement and termination agreement with US firm Bristol-Myers Squibb/Celgene (BMS, NYSE: BMY), formally ending their previous partnership on December 31, 2023. As part of the agreement, both parties have agreed to withdraw arbitral proceedings. Bristol-Myers Squibb/Celgene will transfer 23,273,108 ordinary shares of BeiGene back…
-
Suzhou Jiecheng Medical Secures FDA BDD for Transvascular Aortic Valve Treatment
•
Suzhou Jiecheng Medical Technology Co., Ltd has announced that it has obtained Breakthrough Devices Designation (BDD) from the US Food and Drug Administration (FDA) for its proprietary transvascular interventional biological aortic valve. The device is designed for the treatment of severe aortic valve regurgitation (insufficiency) and mixed aortic valve disease…
-
ABM Therapeutics’ ABM-1310 Earns Orphan Drug Designation for BRAF V600 Mutant Glioblastoma
•
Shanghai-based ABM Therapeutics Inc. has announced that it has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its small molecule BRAF inhibitor, ABM-1310. This designation is in relation to the molecule’s potential use in treating BRAF V600 mutant glioblastoma (GBM), a rare and aggressive…
-
Huaboron Neutron Technology Secures Over RMB 100 Million in Angel Financing for BNCT System
•
Huaboron Neutron Technology (Hangzhou) Co., Ltd (HBNCT) has reportedly secured more than RMB 100 million (USD 13.9 million) in an angel financing round. The round saw participation from notable investors such as Kaitai Capital, Noah Capital, CAS Star, and Kunlun Capital. The funds raised will be directed towards clinical studies…
-
ICE Bioscience Secures Series B+ Financing to Boost Integration Capabilities
•
Beijing-based Contract Research Organization (CRO) ICE Bioscience has reportedly raised close to RMB 100 million (USD 14 million) in a Series B+ financing round. The round was led by Alwin Capital, with additional investments from EVEREST, CICC Capital, Addor Capital, and Root Venture Partners. The funds raised will be directed…
-
Sumitomo Pharma and Otsuka’s Ulotaront Fails to Meet Primary Endpoint in Schizophrenia Trials
•
Japan-based Sumitomo Pharma Co., Ltd (TYO: 4506) and Otsuka Pharmaceutical Co., Ltd (FRA: OS1) have revealed a setback in late-stage clinical trials for the potential first-in-class trace amine-associated receptor 1 (TAAR1) agonist, ulotaront, as a treatment for schizophrenia. Topline data from the Phase III DIAMOND 1 and DIAMOND 2 studies…
